Studies undertaken by experts, and confirmed by pharmaceutical companies, suggest a thriving ‘gray’ market of fake and unapproved copies of oncology and hepatology medicines. Industry experts in India have reported that the majority of these medicines have been manufactured, for export only, by companies in Bangladesh. The experts say that strengthening the border between Bangladesh and India would prevent the illegal entry of the medicines. Unlike other medicines, cancer medicines are not sold through retail chemists, but by distributors. It would, therefore, be relatively easier to trace those involved.
A study in the Indian Journal of Medical Sciences says certain Bangladesh companies are blatantly targeting doctors and patients from across the border by WhatsApp, emails, social media and, in certain cases, are reaching out to patients through pharmacies located near cancer hospitals.
Source : www.timesofindia.indiatimes.comBack to previous